| Authors: |
Shemesh CS; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. shemesh.colby@gene.com., Chanu P; Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France., Jamsen K; Certara Strategic Consulting, Princeton, NJ, USA., Wada R; Certara Strategic Consulting, Princeton, NJ, USA., Rossato G; Clinical Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Donaldson F; Safety Science, Roche Products Ltd, Welwyn Garden City, UK., Garg A; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.; Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA., Winter H; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.; Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA., Ruppel J; Bioanalytical Sciences, Genentech Inc., South San Francisco, CA, USA., Wang X; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA., Bruno R; Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France., Jin J; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA., Girish S; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. |
